Brello Health US Facebook ad: “Tirzepatide Plan from $166/m (3-Month Minimum)”

Running for 67 days since July 31, 2026. Crush last saw it on October 6, 2026.
Run by Brello Health US on Facebook. Crush is not the advertiser and does not verify its claims. See this ad in Meta's Ad Library(opens in a new tab)
Want an ad like this for your product?
Crush makes new ad images for your product from this ad: your logo, your product photo, your offer.
Trials from $19.95 USD, then $79.95 USD a month. Cancel anytime.
About this ad
- Meta Ad Library ID
- 1064246066053992
- Platforms
- Facebook, Instagram, Audience Network, Messenger and Threads
- Relaunches
- 0
Ad text
Thinking about Tirzepatide? Discover how Brello can support you on your journey. We connect you with healthcare professionals who review your information and determine whether a compounded Tirzepatide plan may be appropriate for you. Why choose us? 💙 Supportive private community (12,000+ members) 🧘♀️ Hundreds of fitness & nutrition classes (dancing, yoga, boxing & more!) 📱 All-in-one app: Track progress & log milestones 👩⚕️ Message your care team anytime 📦 Direct-to-door delivery (if approved) Start with a professional evaluation — every prescription decision requires provider review. Any information provided is for informational purposes only and should not be construed as medical advice; it is not a substitute for professional medical consultation, diagnosis, or treatment. All patients must consult with a healthcare provider prior to the prescription or dispensing of any medication, which will be done only pursuant to a valid prescription. Compounded drug products are not FDA-approved, and the FDA does not evaluate their safety, effectiveness, or quality. Patients are encouraged to discuss the risks, benefits, and appropriateness of any medications, including compounded products, with their healthcare provider before use.
Where the ad sends people
brellohealth.com
Tirzepatide Plan from $166/m (3-Month Minimum)
Shop now: brellohealth.com(opens in a new tab)







